132388-58-0

Basic information

• Product Name: N'-Trityl-L-asparagine
• Synonyms: L-ASPARAGINE (TRITYL);H-ASN(TRT)-OH;ASPARAGINE(TRT);N-BETA-TRITYL-L-ASPARAGINE;N-(TRIPHENYLMETHYL)-L-ASPARAGINE;N-γ-Trityl-L-asparagine;H-L-Asn(Trt)-OH;N-.GAMMA.-TRITYL-L-ASPARAGINE
• CAS NO: 132388-58-0
• Molecular Formula: C₂₃H₂₂N₂O₃
• Molecular Weight: 374.43
• Product Categories: Amino Acids Derivatives;Asparagine [Asn, N];Amino Acids and Derivatives
• Mol File: 132388-58-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 641.2 °C at 760 mmHg
• Flash Point: 341.6 °C
• Appearance: White/Powder
• Density: 1.234 g/cm³
• Vapor Pressure: 2.56E-17mmHg at 25°C
• Refractive Index: 1.621
• Storage Temp.: -20°C
• PKA: 2.41±0.10(Predicted)
• CAS DataBase Reference: N'-Trityl-L-asparagine(CAS DataBase Reference)
• NIST Chemistry Reference: N'-Trityl-L-asparagine(132388-58-0)
• EPA Substance Registry System: N'-Trityl-L-asparagine(132388-58-0)

Safety Data

• Hazardous Substances Data: 132388-58-0(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white powder

Uses

Ng-Trityl-L-asparagine is used in preparation of islet amyloid polypeptide.

InChI:InChI=1/C23H22N2O3/c24-20(22(27)28)16-21(26)25-23(17-10-4-1-5-11-17,18-12-6-2-7-13-18)19-14-8-3-9-15-19/h1-15,20H,16,24H2,(H,25,26)(H,27,28)/t20-/m0/s1

Upstream product

• 132388-59-1 L-Asn(Trt) 
• 76-84-6 triphenylmethyl alcohol 
• 132388-57-9 N-benzyloxycarbonyl-N'-trityl-L-asparagine 
• 70-47-3 L-asparagine 

Downstream Products

• 132388-59-1 L-Asn(Trt) 
• 132388-57-9 N-benzyloxycarbonyl-N'-trityl-L-asparagine 
• 1209480-95-4 NVOC-Asn(Trt)-OH 
• 1638884-72-6 N_α-(phenoxycarbonyl)-N_γ-trityl-L-asparagine 
• 1542167-13-4 tert-butyl 4-((S)-3-(((S)-1-(tert-butyloxy)-1-oxopropan-2-yl)amino)-2-(2-((5S,8S)-6-(tertbutoxycarbonyl)-8-carbamoyl-12,12-dimethyl-3,10-dioxo-1,1,1-triphenyl-11-oxa-2,6,9-triazatridecan-5-yl)-6-((tert-butyloxycarbonyl)amino)pyrimidine-4-carboxamido)-3-oxopropyl)-1H-imidazole-1-carboxylate 
• 1542167-12-3 2-((5S,8S)-6-(tert-butyloxycarbonyl)-8-carbamoyl-12,12-dimethyl-3,10-dioxo-1,1,1-triphenyl-11-oxa-2,6,9-triazatridecan-5-yl)-6-((tert-butyloxycarbonyl)amino)pyrimidine-4-carboxylic acid 
• 1542167-10-1 tert-butyl 2-((5S,8S)-6-(tert-butyloxycarbonyl)-8-carbamoyl-12,12-dimethyl-3,10-dioxo-1,1,1-triphenyl-11-oxa-2,6,9-triazatridecan-5-yl)-6-((tert-butyloxycarbonyl)amino)-pyrimidine-4-carboxylate 
• 1542167-09-8 (S)-3-((tert-butyloxycarbonyl)((S)-1-(4-(tert-butyloxycarbonyl)-6-((tert-butyloxycarbonyl)-amino)pyrimidin-2-yl)-3-oxo-3-(tritylamino)propyl)amino)-2-((tert-butyloxycarbonyl)-amino)propanoic acid 
• 1542167-08-7 tert-butyl 2-((5S,8S)-6-(tert-butoxycarbonyl)-8-(hydroxymethyl)-12,12-dimethyl-3,10-dioxo-1,1,1-triphenyl-11-oxa-2,6,9-triazatridecan-5-yl)-6-((tertbutoxycarbonyl)amino)pyrimidine-4-carboxylate 
• 1542167-07-6 tert-butyl (S)-4-(((tert-butyloxycarbonyl)((S)-1-(4-(tert-butyloxycarbonyl)-6-((tertbutyloxycarbonyl)amino)pyrimidin-2-yl)-3-oxo-3-(tritylamino)propyl)amino)methyl)-2,2-dimethyloxazolidine-3-carboxylate 
• 1542167-06-5 4-(tert-butyl) 6-ethyl 2-((S)-1-((tert-butyloxycarbonyl)(((S)-3-(tert-butyloxycarbonyl)-2,2-dimethyloxazolidin-4-yl)methyl)amino)-3-oxo-3-(tritylamino)propyl)pyrimidine-4,6-dicarboxylate 
• 1542167-05-4 4-(tert-butyl) 6-ethyl 2-((S)-1-((((S)-3-(tert-butyloxycarbonyl)-2,2-dimethyloxazolidin-4-yl)methyl)amino)-3-oxo-3-(tritylamino)propyl)pyrimidine-4,6-dicarboxylate 
• 1542166-98-2 tert-butyl 2-((5S,8S)-6-(tert-butyloxycarbonyl)-8-carbamoyl-12,12-dimethyl-3,10-dioxo-1,1,1-triphenyl-11-oxa-2,6,9-triazatridecan-5-yl)-6-((tert-butyloxycarbonyl)amino)-5-methylpyrimidine-4-carboxylate 
• 1542166-97-1 (S)-3-((tert-butyloxycarbonyl)((S)-1-(4-(tert-butyloxycarbonyl)-6-((tertbutyloxycarbonyl)amino)-5-methylpyrimidin-2-yl)-3-oxo-3-(tritylamino)propyl)amino)-2-((tert-butyloxycarbonyl)amino)propanoic acid 

Relevant articles and documents

Cystobactamid 507: Concise Synthesis, Mode of Action, and Optimization toward More Potent Antibiotics

Lack of new antibiotics and increasing antimicrobial resistance are among the main concerns of healthcare communities nowadays, and these concerns necessitate the search for novel antibacterial agents. Recently, we discovered the cystobactamids—a novel natural class of antibiotics with broad-spectrum antibacterial activity. In this work, we describe 1) a concise total synthesis of cystobactamid 507, 2) the identification of the bioactive conformation using noncovalently bonded rigid analogues, and 3) the first structure–activity relationship (SAR) study for cystobactamid 507 leading to new analogues with high metabolic stability, superior topoisomerase IIA inhibition, antibacterial activity and, importantly, stability toward the resistant factor AlbD. Deeper insight into the mode of action revealed that the cystobactamids employ DNA minor-groove binding as part of the drug–target interaction without showing significant intercalation. By designing a new analogue of cystobactamid 919-2, we finally demonstrated that these findings could be further exploited to obtain more potent hexapeptides against Gram-negative bacteria.

N-METHYL AMINO ACIDS

The present invention relates to a compound of formula (I) or (II), processes for preparing them, peptides including them and kits involving them.

Protected amino acids and process for the preparation thereof

Compounds of the formula I, STR1 in which 'R1 is an amino protective group, and n stands for 1 or 2, R1 denotes hydrogen or an amino protective group, R2 denotes hydrogen or a carboxyl protective group and R3 denotes triphenylmethyl, 4-monomethoxy-trityl or 4,4'-dimethoxy-trityl, and reactive carboxylic acid derivatives of such compounds of the formula I in which R2 stands for hydrogen, are described. These compounds can be used as starting materials for the preparation of peptides. They are more suitable for this than are analogous compounds of the formula I in which R3 denotes hydrogen or one of the carbamoyl protective groups hitherto customary.